Posts by acn:

Doubleview Gold Corp. Reports Updated Mineral Resource Estimate as of February 25, 2026 Including a Copper Equivalent Mineral Resource: 609 (Mt) of Measured and Indicated Resources at 0.43% CuEq containing CuEq 5.82 Billion lbs. 503 (Mt) of Inferred Resources at 0.41% CuEq containing CuEq 4.57 Billion lbs

Resource estimate highlights:Measured Mineral Resources of 272 million tonnes (Mt), Indicated Mineral Resources of 337 Mt, and Inferred Mineral Resources of 503 Mt at a 0.2% copper equivalent (CuEq) cut-off grade, or272 Mt of Measured Mineral Resources, expressed in contained metal, total 2.61 billion pounds (Blb) of copper equivalent (CuEq) at 0.44% CuEq, including 1.11 Blb of copper, 35.6 million pounds (Mlb) of cobalt, 1.41 million ounces (Moz) of gold, and 2.17 Moz of silver. (Table 1)337 Mt of Indicated Mineral Resources, expressed in contained metal, total 3.21 Blb of 0.43% CuEq, including 1.31 Blb of copper, 44.5 Mlb of cobalt, 1.81 Moz of gold, and 2.88 Moz of silver. (Table 1)509 Mt of Inferred Mineral Resources, expressed in contained metal, total 4.57 Blb of 0.41% CuEq, including 1.72 Blb of copper, 66.2 Mlb of cobalt, 2.77 Moz of gold, and 4.19 Moz of silver. (Table 1)Scandium Resource: The deposit hosts 609 Mt in the Measured and Indicated categories (containing approximately 17,510 tonnes of scandium) and 504 Mt in the Inferred category (containing approximately 14,465 tonnes of scandium). Scandium has been incorporated into the Mineral Resource Estimate and under current processing constraints, is limited to 12.5% of tailings using internally generated acid. The scandium resource is estimated at 76 Mt Measured and Indicated at 28.8 g/t Sc (containing 2,189 tonnes of scandium) and 63 Mt Inferred at 28.7 g/t Sc (containing 1,808 tonnes of scandium).Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - February 25, 2026) - Doubleview Gold Corp (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) ("Doubleview" or the "Company") is pleased to announce the update of the Mineral Resource estimate (MRE) of its 100%-owned polymetallic Hat porphyry project (Hat), in northwestern British Columbia. With major content of copper, gold, cobalt and silver, as well as scandium, Hat becomes an important source of critical minerals.Farshad Shirvani, president and CEO of Doubleview Gold Corp commented, "Year by year, the size of the deposit was increased by very targeted drilling, bringing it to a footprint of about 1.6 km by 1.6 km. I appreciate my technical and management team in this endeavour. We've discovered numerous additional elements within the Hat deposit that will soon be unveiled, each further showcasing the deposit's uniqueness and enhancing the resource."Summary of MRE for Hat Deposit:Table 1: Hat MRE at a 0.2% CuEq Cut-Off Effective February 4, 2026,(Base-Case Scenario to be Presented in the Technical Report)Mineral Resource ClassificationTonnage(Mt)Average GradeMetal ContentCuEq(%)Cu(%)Au(g/t)Co(%)Ag(g/t)CuEq(Blb)Cu(Blb)Au(Moz)Co(Mlb)Ag(Moz)Measured2720.440.220.180.0080.372.611.111.4135.62.17Indicated3370.430.210.190.0080.393.211.311.8144.52.88Total M+I6090.430.210.180.0080.385.822.423.2280.15.05Inferred5030.410.180.190.0080.384.571.722.7766.24.19 Table 2: Hat MRE at a 0.2% CuEq Cut-Off as of February 4, 2026, Scandium Oxide ResourcesMineral Resource ClassificationTonnage(Mt)Sc Tonnage1(Mt)Average GradeSc (g/t)Metal ContentSc2O3 2 (t)Measured2723428.791,081Indicated3374228.761,334Total M+I6097628.772,415Inferred5036328.691,996 Notes: 1 Scandium tonnages represent 12.5% of the mineralized material by category, reflecting the proportion of tailings expected to be processed through a dedicated scandium leach circuit under current metallurgical design constraints.2 Scandium oxide metal content have been calculated using the metallurgical recovery of 72% and conversion factor from Sc to Sc2O3 of 1.534. Mineit's Qualified Person, Tomasz Wawruch, FAusIMM, completed the MRE, and has reviewed and approved the technical disclosure related to the MRE contained in this news release. Mr. Wawruch is a senior geology and mineral resource consultant independent of Doubleview. Mr. Gilles Arseneau, PhD., P.Geo., of ARSENEAU Consulting Services Inc., provided an independent review of this MRE.Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues.Inferred Mineral Resources are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as Mineral Reserves. The Mineral Resource Estimate was prepared in accordance with the Canadian Institute of Mining, Metallurgy and Petroleum ("CIM") Definition Standards for Mineral Resources and Mineral Reserves (2014), and CIM MRMR Best Practice Guidelines (2019).The effective date of the MRE is February 4, 2026.Metal contents have been calculated using the following metallurgical recovery factors: Cu = 85%, Au = 89%, Co = 78%, and Ag = 68%.Economic assumptions used include US$4.80/lb Cu, US$20.00/lb Co, US$3,200/oz Au, US$46/oz Ag, and a 2% NSR royalty.Mineral Resources are reported within optimized open pit constraints and 0.2% CuEq cut-off grade, based on a C$7.93/t milled processing cost and C$2.90/t milled general and administrative cost, with a mining cost of C$3.01/t plus incremental mining cost increasing by C$0.015/t for every bench below the reference level of 1,125 mRL.CuEq calculations do not include scandium. The formula used to calculate CuEq is: CuEq = [(((Ag × 46.0 × 0.68)/31.1035) + ((Au × 3200 × 0.89)/31.1035) + 0.0001 × (Co × 20.0 × 0.78 × 22.0462) + 0.0001 × (Cu × 4.8 × 22.0462 × 0.85))/(4.8 × 22.0462 × 0.85)], where all input variables are expressed in (ppm) and CuEq is expressed in percent (%).Rounding may result in minor variations between individual values and totals; such differences are not considered material to the MRE.Mineral Resource classification reflects the level of geological confidence and satisfies the uncertainty criteria appropriate for exploration and resource development. Additional drilling will be required to reduce uncertainty to the level expected for production planning. The MRE reflects the geological interpretation, drill-hole spacing, and estimation parameters available at the time of modelling. Any additional drilling is expected to influence the current outcome by improving confidence in the estimates and refining the geometry of the mineralized domains.The Mineral Resource results are presented in situ within the optimized pit. Mineralized material outside the pit has not been considered as a part of the current MRE tabulation. Calculations used metric units (metres, tonnes, g/t).A total of 97 diamond drill holes, comprising 49,548 m of core, were incorporated into the Mineral Resource Estimate. All drilling data used in the MRE were subject to standard QA/QC validation prior to inclusion.The block model is defined relative to a model origin at UTM Zone 9N 346,750 E / 6,453,000 N / 0 (NAD 83). Parent blocks measure 15 × 15 × 15 m, totalling 136 × 150 × 75 blocks across extents of 2,040 m (X), 2,250 m (Y), and 1,125 m (Z). All volumes and estimates are constrained by these discretization parameters. Figure 1: Plan View at 715 m ASL of the Block Model Showing the Distribution of Equivalent Copper Grade Within the Optimized 120 Kilotonne per Day (kt/d) Pit Shell Outline (UTM Zone 9N [NAD 83])To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/285247_b57c38042424daa0_001full.jpgFigure 2: Cross-Section of East 348000 Looking West of the Block Model Showing the Distribution of Equivalent Copper Grade Within the Optimized 120 kt/d Pit Shell Outline (UTM Zone 9N [NAD 83])To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/285247_b57c38042424daa0_002full.jpgFigure 3: Plan View at 715 m ASL of the Block Model Showing the Distribution of Equivalent Copper Classification Within the 120 kt/d Optimized Pit Shell Outline (UTM Zone 9N [NAD 83])To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/285247_b57c38042424daa0_003full.jpgFigure 4: Cross-Section of East 348000 Looking West of the Block Model Showing the Distribution of Equivalent Copper Classification Within the 120 kt/d Optimized Pit Shell Outline (UTM Zone 9N [NAD 83])To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/285247_b57c38042424daa0_004full.jpgThe Hat DepositThe Hat Claims property consists of 16 mineral tenures covering 13,823.09 hectares north of the Golden Bear mine road in northwest B.C. For additional information please visit www.doubleview.ca.Mineit Consulting Inc (Mineit) prepared the MRE in accordance with CIM Definition Standards on Mineral Resources and Reserves on Mineral Resources and Reserves. A Technical Report in support of the MRE will be filed on SEDAR+ (www.sedarplus.ca) within 45 days.Tomasz Wawruch, FAusIMM, of Mineit, is the Qualified Person for the MRE, and has reviewed and approved the technical disclosure related to the MRE contained in this news release. Mr. Wawruch is a geology and mineral resource consultant independent of Doubleview. Gilles Arseneau, PhD., P.Geo of ARSENEAU Consulting Services Inc. provided an independent peer review of the MRE and did not identify any fatal flaws with the resource model prepared by Tomasz Wawruch.With respect to the Hat Project metallurgical studies, EUR ING Andrew Carter, B.Sc., CEng., MIMMM QMR, MSAIMM SME, of Magister Metallurgy, is Doubleview's Qualified Person, as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects; he has reviewed and approved the technical contents of this news release. Mr. Carter is independent of Doubleview.About Doubleview Gold Corp.Doubleview Gold Corp., a mineral resource exploration and development company based in Vancouver, British Columbia, Canada, is publicly traded on the TSX-Venture Exchange (TSXV: DBG), the OTCQB (OTCQB: DBLVF), the Berlin Stock Exchange [GER: A1W038], and the Frankfurt Stock Exchange [1D4]. Doubleview identifies, acquires, and finances precious and base metal exploration projects in North America, particularly in British Columbia. The Company increases shareholder value through the acquisition and exploration of quality gold, copper, cobalt, scandium, and silver properties—collectively critical minerals—and through the application of advanced, state-of-the-art exploration methods. Doubleview's portfolio of strategic properties provides diversification and mitigates investment risk.On behalf of the Board of Directors,Farshad Shirvani, President & Chief Executive OfficerFor further information please contact:Doubleview Gold CorpVancouver, BCFarshad ShirvaniPresident & CEOInstitutional Line: (604) 607-5470T: (604) 678-9587E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Certain of the statements made and information contained herein may constitute "forward-looking information." In particular references to the Mineral Resource Estimate and future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of. Accordingly, readers are advised not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285247 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

analytica Hanoi 2026 Makes Its Debut, Bringing the Global Science and Laboratory Platform to Northern Vietnam

- Exhibition space fully secured prior to the show, reflecting strong exhibitor confidence in Northern Vietnam’s laboratory and scientific markets- Over 150 international and local exhibitors & brands confirmed from USA, Germany, Japan, Korea, Taiwan, Singapore, Switzerland, France, India, Vietnam and China & more- Expanded Live Lab, following its debut in Ho Chi Minh 2025, now making its first appearance in HanoiHANOI, Vietnam, Feb 25, 2026 - (ACN Newswire via SeaPRwire.com) - analytica Hanoi 2026, the regional edition of the globally recognised analytica brand, will take place from 22–24 April 2026 at the International Centre of Exhibition (I.C.E), Hanoi. Tailored to the needs of Northern Vietnam's science and laboratory community, the exhibition space is fully secured ahead of opening, reflecting strong market demand and the growing importance of Vietnam as a laboratory and innovation hub."Northern Vietnam is rapidly emerging as a hub for laboratory innovation. With analytica Hanoi 2026, we are bringing the Live Lab to Hanoi for the first time, following its successful debut in Ho Chi Minh 2025. This demonstrates our commitment to connecting international solution providers with the region’s growing scientific and industrial community," said Michael Wilton, CEO and Managing Director, Messe Muenchen International Asia Pte, Ltd.Broad International Participation Reflects Market Relevanceanalytica Hanoi 2026 will feature over 150 exhibitors and brands from key laboratory and technology markets including USA, Germany, Japan, Korea, Taiwan, Singapore, Switzerland, France, India, Vietnam, Latvia, China etc. highlighting its strong global reach. This edition builds on the success of previous analytica Vietnam shows, offering a dedicated platform for technology exchange, business networking and market access tailored to Northern Vietnam.The exhibition will showcase laboratory instruments, analytical systems, biotechnology and diagnostics solutions, quality assurance technologies, and sustainable laboratory operations, meeting the evolving needs of the region’s laboratory and research sectors.Live Lab Makes Its Northern DebutFollowing its successful debut at analytica Vietnam Ho Chi Minh 2025, the Live Lab is coming to Hanoi for the first time in 2026. This interactive zone allows exhibitors to present hands-on demonstrations of laboratory technologies and real-world applications, enabling visitors to directly experience workflows, assess performance, and explore practical solutions.By bringing this pioneering format to Northern Vietnam, analytica Hanoi 2026 provides a first-of-its-kind experiential platform in Hanoi, offering laboratory professionals, researchers, and industrial users a unique opportunity to engage with both international and local technology providers in a practical, applied setting.Northern Vietnam Strengthens Its Role as a Growth MarketNorthern Vietnam is a key driver of Vietnam’s science and technology-led industrial upgrading, with strong investment across pharmaceuticals, healthcare, electronics, food safety, environmental monitoring, and advanced manufacturing. These sectors underpin national priorities on innovation, quality infrastructure, and sustainable growth, increasing demand for advanced laboratory technologies and digitalised operations.Building on this momentum, analytica Hanoi 2026 supports national science & technology objectives as a platform for knowledge exchange, standards alignment, and technology adoption.The event features a two-stage programme. The Academic Conference, jointly organised by Messe München, the Vietnam Analytical Sciences Society (VASS), VNU University of Science (HUS) – Vietnam National University, and VNEES, contributes to knowledge advancement and talent development in priority fields including green and environmental chemistry, food safety and quality control, semiconductor manufacturing, and molecular biology applications in biopharma and pharmacogenomics. The Technical Forum reinforces quality infrastructure and regulatory readiness, addressing ISO/IEC 17025, GLP, the laboratory outlook for 2026–2030, and applied seminars, complemented by exhibitor technology sessions.A Trusted Platform for Business and KnowledgeThe full occupancy of exhibition space underscores analytica Hanoi’s role as a reliable platform linking global technology providers with Northern Vietnam’s laboratory and research community. Confirmed exhibitors include WESTINGAREA, WIGGENS, GL SCIENCES, BCE, CHC LAB, DAIHAN SCIENTIFIC, ANTON PAAR, KIMTECO, LECO VIETNAM, GLASS TAO, FOSS VIETNAM, HTI SCIENTIFIC, MERCK VIETNAM, UNITEK and many more.Supporting programmes such as live demonstrations, hosted buyer engagements, and structured business matching further enhance opportunities for business development and collaboration.REGISTRATION NOW OPENanalytica Hanoi 2026 is expected to attract laboratory professionals, researchers, manufacturers, distributors, and institutional representatives from across Vietnam and the region.Visitor registration is now open:https://registration.analyticavietnam.com.vn/en/reg/analytica-vietnamFor more information, please visit www.analyticavietnam.comor contact analytica Vietnam via email analyticavietnam@mmiasia.com.sgAbout analytica Hanoi 2026analytica Hanoi is the official regional spinoff of analytica Vietnam, strategically developed to meet the rising demand for laboratory and analytical solutions in northern Vietnam. As the region experiences accelerated growth in research, healthcare, and industrial sectors, analytica Hanoi 2026 offers a focused platform for companies aiming to tap into this dynamic and fast-emerging market. The upcoming exhibition is set to take place from April 22 to 24, 2026 at the International Centre of Exhibition (I.C.E), 91 Tran Hung Dao, Hanoi, Vietnam.About analytica Vietnam 2027analytica Vietnam is the premier trade fair for laboratory technology, analysis, and biotechnology in Southeast Asia. Organized by Messe München, the event brings together industry professionals, researchers, and policymakers to showcase the latest technologies, exchange knowledge, and foster business collaborations. analytica Vietnam features an exhibition, conference, pre-event laboratory tours, buyer-seller programs, and networking opportunities, providing a comprehensive platform for the laboratory and biotechnology industries in the region. The upcoming edition is set to take place from March 31 to April 2, 2027 at the Saigon Exhibition and Convention Center (SECC), 799 Nguyen Van Linh, Ho Chi Minh City, Vietnam. More details can be found here.About analytica worldwideFor over five decades, analytica has been the leading international trade fair series for laboratory technology, analysis, and biotechnology. Organized by Messe München, the series includes analytica in Munich, analytica China, analytica Anacon India, analytica USA, analytica Vietnam, and now, analytica Hanoi. Additional information about these exhibitions and their programs of events is available at www.analytica.de.About MMI Asia Pte LtdEstablished in 1992, MMI Asia is the wholly owned subsidiary and the regional headquarters of Messe München GMBH (MMG) and is one of the world largest and leading exhibition organizers. MMI Asia’s portfolio of events include editions of world-leading trade fairs from Munich – transport logistic & air cargo, analytica, ceramitec; as well as industry-specific events such as Glasstech and Fenestration Asia, Asia Climate Forum, and Singapore International Water Week. MMI Asia also provides consultancy in professional trade fair and conference management to government bodies, international trade and promotion organizations, and trade associations. For more information, please visit www.mmiasia.com.About Messe MünchenAs one of the world’s leading trade fair organizers, Messe München presents the world of tomorrow at its about 90 trade fairs worldwide. These include twe lve of the world’s leading trade fairs such as bauma, BAU, IFAT, electronica, and ISPO. Messe München’s portfolio comprises trade fairs for capital and consumer goods, as well as for new technologies. Together with its subsidiaries, it organizes trade fairs in China, India, Brazil, South Africa, Turkey, Singapore, Vietnam, Hong Kong, Thailand, and the U.S. With a network of more than 15 affiliated companies and almost 70 representations worldwide, Messe München is active in more than 130 countries. The more than 150 events held annually attract around 50,000 exhibitors and around three million visitors in Germany and abroad.Exhibition Contact:MMI Asia Pte. Ltd.Siegli L. BacudioProject Managersiegli@mmiasia.com.sgPress Contact:MMI Asia Pte. Ltd.Shae NguyenMarketing Executiveshae@analyticavietnam-exhibitions.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

周大福人壽支持《財政預算案》有關跨境安老、落實《香港可持續披露準則》以及推動體育普及化、盛事化等措施

香港, 2026年2月25日 - (亞太商訊 via SeaPRwire.com) -  周大福人壽支持《2026-27年度財政預算案》(《財政預算案》)中提出有關跨境安老、落實《香港可持續披露準則》以及積極推動體育普及化、盛事化的多項舉措。周大福人壽執行董事兼行政總裁葉文傑表示:「作為扎根香港40年的保險公司,周大福人壽持續創新產品,並不斷擴展中國內地與香港兩地醫療服務網絡等安排,以配合政府支持跨境安老的措施。在可持續發展方面,我們與政府抱持共同願景,早前自願發佈符合本地及國際披露標準的ESG報告,未來亦會繼續將可持續發展融入業務策略。在體育盛事化方面,我們將以啟德體育園獨家創始保險合作夥伴的身份,支持政府推動香港體育普及化及盛事化發展,以及未來體育精英的培育,開創保險新價值。」他續稱:「同時,周大福人壽歡迎《財政預算案》中優化保險公司風險為本的資本制度,以及逐步推行強積金『全自由行』等舉措,從而提升市場信心及整個保險業界的專業水平。」持續優化跨境安老服務《財政預算案》提出支持跨境安老,包括「廣東院舍照顧服務計劃」本月起新增至26家,覆蓋大灣區內地9個城市。周大福人壽相信這些舉措有助改善醫療及安老服務配套,公司除了在產品中加入中國內地與香港兩地醫療服務保障覆蓋,今年初更進一步擴展「直接支付服務」網絡至多個大灣區城市的公私營醫院。未來周大福人壽將持續優化醫療保險產品及服務體系,為北上南下客戶提供更貼合生活需要的方案。積極推動綠色金融發展為配合政府鞏固香港國際綠色金融中心地位,周大福人壽一直將可持續發展融入業務策略。今年1月,公司自願發佈獨立環境、社會及管治(ESG)報告,是領先業界的舉措。此舉與政府落實《香港可持續披露準則》、推動跨界別合作的願景一致,我們將合力推動綠色金融發展。致力培育體壇新星《財政預算案》中提及政府將積極推進體育普及化、精英化、盛事化、專業化和產業化,並爭取舉辦更多大型國際體育賽事和活動。作為啟德體育園的獨家創始保險合作夥伴,周大福人壽將與啟德體育園加強合作,公司去年開始冠名贊助飛越啟德「小劍神」培訓計劃,與政府文體旅發展策略相輔相成,同時發揮協同效應,繼續支持新晉運動員邁向國際,成就未來世界冠軍。關於周大福人壽周大福人壽保險有限公司(「周大福人壽」)扎根香港40年,為周大福創建有限公司(「周大福創建」)(香港股份代號:659)的全資附屬公司,也是香港最具規模的壽險公司之一。作為周大福企業成員,周大福人壽緊扣鄭氏家族(「周大福集團」或「集團」)生態圈的雄厚資源,致力為客戶及其摯愛於「生活、成長、健康、傳承」的人生旅程中,提供個人化的匠心規劃、終身保障及優質體驗。憑藉集團財務實力及環球投資佈局,周大福人壽矢志成為亞太區領先的保險公司,持續開創保險新價值。周大福人壽保險有限公司(於百慕達註冊成立之有限公司) Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HKTDC welcomes the 2026-27 Budget

HONG KONG, Feb 25, 2026 - (ACN Newswire via SeaPRwire.com) – The Hong Kong Trade Development Council (HKTDC) welcomes the 2026–27 Budget delivered this morning by the Financial Secretary of the Hong Kong Special Administrative Region (HKSAR), Paul Chan. The Budget reflects the HKSAR Government’s determination and proactive approach to growing the economy, driving development and improving people’s livelihoods. It focuses on strengthening Hong Kong’s status as an international centre for financial, trade, shipping and I&T, while accelerating new industrialisation and digital transformation.The Budget also supports enterprises in integrating into the country’s overall development and seizing opportunities under the 15th Five-Year Plan. This includes continuously improving the business environment, promoting artificial intelligence and green sustainable development, as well as implementing various measures to consolidate Hong Kong’s unique advantages in connecting the Chinese Mainland and the world.Prof Frederick Ma, Chairman of the HKTDC, said: “The HKTDC welcomes the forward-looking measures in the Budget, including the announcement of the city’s first five-year plan and injecting HK$200 million into the BUD Fund. These initiatives demonstrate the HKSAR Government’s commitment to supporting Hong Kong SMEs and facilitating economic transformation and high-quality development. We will actively align with the Government’s policy direction, implement the national 15th Five-Year Plan, and support Hong Kong in consolidating and enhancing its position as an international financial, shipping and trading centre, while establishing the city as an international hub for I&T and high calibre talents.We will also extend our global business network, further deepen our ties with the ASEAN and Middle Eastern markets and explore more emerging markets. These efforts will further enhance Hong Kong’s pivotal role in the Belt and Road Initiative.”Prof Ma added: “As a superconnector and super value-adder, Hong Kong enjoys the unique edge of linking the mainland and global markets. We successfully bring in international capital, technology, talents and advanced management expertise, helping mainland and local enterprises upgrade and innovate, while supporting mainland companies to go global via Hong Kong’s professional services platform.“As a core member of the GoGlobal Task Force, the HKTDC will further leverage its network of 51 offices worldwide to help businesses explore global markets, diversify risks and achieve growth. We will continue to provide value-added services to Hong Kong enterprises, especially SMEs, empowering them to capitalise on e-commerce opportunities, drive their digital transformation and enhance their competitiveness.”Comprehensive Go-Global Support ServicesThe HKTDC will strengthen its diverse business platforms, including international exhibitions, conferences, business matching, market intelligence and e-commerce support, offering one-stop comprehensive go global assistance, covering brand promotion, supply chain management, professional services matching and risk management.The HKTDC will roll out more concrete measures and support programmes to help Hong Kong and mainland enterprises capitalise on national development strategies and global market opportunities and expand their international business in a sustainable manner.Strengthening I&T ecosystem to help enterprises capture opportunitiesThe Budget introduced a range of measures to promote Hong Kong’s development as an international I&T hub. The HKTDC will continue to actively support the HKSAR Government by integrating I&T elements into its exhibitions, conferences and events. These platforms will help promote Hong Kong’s I&T strengths and ecosystem advantages to mainland and overseas markets, foster cross-industry and cross-regional collaboration and incorporate IP elements to enhance overall competitiveness and effectively protect innovation outcomes.As the flagship event of the Business of Innovation and Technology Week (BIT Week) jointly organised by the Innovation, Technology and Industry Bureau of the HKSAR Government and the HKTDC, InnoEX will once again take place in April to showcase cutting-edge technologies and global innovations, as well as accelerate technology commercialisation and achieve sustainable growth.The HKTDC will continue to leverage Hong Kong’s unique advantages as a global business hub, using its flagship events, efficient business matching and professional service connections to support businesses expand internationally.The Budget also notes that the Asian Financial Forum (AFF) will celebrate its 20th anniversary next year. The HKTDC will work closely with the HKSAR Government to further strengthen AFF’s focus on finance empowering business (Finance +), by leveraging on the Global Business Summit, to enable the financial sector to better serve the real economy and industries with a competitive edge.Media enquiriesHKTDC’s Communications & Public Affairs Department:Agnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgSam HoTel: (852) 2584 4569Email: sam.sy.ho@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Hong Kong Tech Delegation Heading for Market Expansion at Mobile World Congress 2026

HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – Hong Kong Trade Development Council (HKTDC), in collaboration with Hong Kong Science and Technology Parks Corporation (HKSTP), will lead a delegation of 21 Hong Kong tech companies and institutions to showcase at Mobile World Congress (MWC) 2026—the world’s premier connectivity event, and debut at 4 Years From Now (4YFN) 2026—a global stage for start-ups, taking place concurrently 2-5 March in Barcelona, Spain.  Building on the momentum from MWC 2025 — the Delegation will be featuring solutions beyond the Connectivity category, covering focus areas across Devices and Systems, Digital Transformation and support from Ecosystem Partners. The Pavilion duet ought to give a more comprehensive picture of Hong Kong’s innovation and technology (I&T) capabilities in engaging global telecom leaders, enterprise decision-makers, industry partners, and investors, bridging cutting-edge research and development (R&D) into real-world applications and propelling Hong Kong’s I&T sector onto the international stage.Iris Wong, Director, Merchandise Trade and Innovation / Director, External Relations, HKTDC, said, “The Hong Kong Tech Pavilion is an ideal platform for Hong Kong tech enterprises to present their latest R&D achievements at major international tech gatherings, support their journey to explore overseas markets, while highlighting Hong Kong’s strengths as an international innovation and technology hub.”Derek Chim, Head of Startup Ecosystem and Development, HKSTP said, “MWC is a global bellwether for communications technology and tech companies at any stage, to connect with the industry and investors, to have a solid ground that validate solutions, catalyse pilot projects, accelerate commercialisation, and scale internationally.”A series of dialogues and exchanges, spanning from networking reception and themed talks to pitching sessions, will take place throughout the events at the Pavilion to facilitate partnerships and investment opportunities for innovative solutions that are market-ready with high potential for market expansion, in particular, Asmote and Cresento under “Connectivity” make stellar examples of the notion:5G & 6G for Communication, Sensing, and AI computing – Shannon & Turing, (Asmote), located at MWC, specialises in mmWave technology for Integrated Sensing and Communication (ISAC) technology—drone communications and control—rising to the occasion as the city advances its low-altitude economy initiatives, while winning favors for its efficiency in managing industrial scenarios such as smart ports and dark factories. The company previously secured the world’s first 26GHz mmWave 5G commercial communications project, demonstrating its leadership in industrial-grade applications.Smart Performance Insights for Sport – Cresento, located at 4YFN, focused on developing an AI-powered shin guard to deliver real-time insights—performance analytics, team leaderboards, and more—with a design that incorporates into gears that athletes already wear and creates minimal friction for, in particular, football players to adapt, will be moving from prototypes to pilot collaborations with European football clubs, academies and sport tech platforms and distributors.HKTDC continues to join hands with HKSTP to support Hong Kong tech enterprises to “go global” by jointly organising the Hong Kong Tech Pavilion to build bridges linking tech companies with the world. This expedites the industry’s progress in internationalisation to meet the growing demand for I&T globally. This will attract talents, facilitate forward-looking investments and explore opportunities globally, realising the mission of entrepreneurs to reach out to the world and further consolidate Hong Kong’s position as an international I&T hub.Mobile World Congress Barcelona (MWC) & 4 Years From Now (4YFN)Date: 2-5 March 2026Venue: Fira Gran Via, Av. Joan Carles I, 64, 08908 L'Hospitalet de Llobregat, Barcelona, SpainHong Kong Tech Pavilion:MWC – Booth 6E44 at Hall 64YFN – Booth 8.1B31 at Hall 8.1Please visit https://bit.ly/MWC2026HKTech for more information on Hong Kong Tech Pavilion and the exhibitors.Appendix: Full list of 21 tech entities showcasing at Hong Kong Tech Pavilion during MWC and 4YFN 2026 (in alphabetical order)No.Name of Tech Company / InstitutionCategoryMWC 2026 – Booth 6E44 at Hall 61Entoptica LimitedDevices & Systems2eSIXConnectivity3Faraconix Technologies Co., Ltd.Connectivity4FreightAmigo Services LimitedDigital Transformation5Glassdio Scientific Company LimitedConnectivity6Harvest Elite International LimitedDigital Transformation7HongKong Umedia LimitedDevices & Systems8iASPEC Services LimitedDigital Transformation9InvestHKEcosystem Partners10Robocore Technology LimitedDevices & Systems11Shannon & Turing Technology LimitedConnectivity12The Hong Kong Polytechnic UniversityEcosystem Partners13Xeroptix TechnologyDevices & Systems4YFN 2026 – Booth 8.1B31 at Hall 8.114AIGM LimitedDigital Transformation15BWSea Technology (HK) Co., LimitedDigital Transformation16Cresento LimitedDevices & Systems17GoGoChart Technology LimitedDigital Transformation18HairCoSys LimitedDevices & Systems19KNQ Technology LimitedDigital Transformation20Solos Technology LimitedDevices & Systems21Vista Innotech LimitedDevices & SystemsAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.About Hong Kong Science and Technology Parks CorporationHong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 12 unicorns, more than 16,000 research professionals and around 2,600 technology companies from 24 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.More information about HKSTP is available at www.hkstp.org.Media Contact: Hong Kong Science and Technology Parks CorporationHong Kong Trade Development CouncilAngela LauTel: +852 6535 7611Email: angela.lau@hkstp.orgWinnie KanTel:  +852 2584 4055Email: winnie.wy.kan@hktdc.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

維昇藥業(2561.HK)維臻高(R)獲批:重長效生長激素王者登場 重構百億市場的商業天花板

香港, 2026年2月24日 - (亞太商訊 via SeaPRwire.com) - 2026年2月2日,維昇藥業於上海舉辦維臻高(R)(注射用隆培生長激素)獲批上市投資者交流會。 該產品已於1月26日獲得國家藥品監督管理局批准上市。公司在會上表示,維臻高(R)被定位為具備里程碑意義的創新產品 - 不僅是首個在歐美獲批用於兒童的長效生長激素,也是目前臨床研究中唯一被證實在療效上優於日製劑的長效生長激素產品。在生長激素賽道中,隨著多款產品陸續納入醫保、價格體系快速下探,市場競爭格局正在發生變化。維昇藥業以臨床價值和技術壁壘為核心,打造差異化的高端產品路徑。本次交流會由公司管理層系統介紹了產品研發邏輯、臨床數據及當前階段商業化策略的核心思路。本次會議邀請了多位合作夥伴與行業嘉賓出席,包括國婦嬰主任醫師餘文教授、安科生物高級副總裁姚建平先生、副總裁鮑學科先生、上藥控股副總經理宋潞潞女士、上海和睦家醫院長寧院區執行院長劉曉龍先生等到場支持。同時,公司長期股東代表——碧沃投資合夥人柳丹先生亦出席交流,體現了核心股東對公司商業化路徑與長期價值的持續認可。中信證券、東吳證券、天風證券和國海證券等多家大型券商及投資機構亦參與本次會議。一、產品內核:技術壁壘構建差異化護城河1.1 "暫時連接"技術的獨特性在生長激素領域,由於技術壁壘高,實現長效化與保持活性分子的天然結構長期被視為"魚與熊掌不可兼得",而維臻高(R)的研發上市成功突破這一行業技術壁壘,是全球首款實現"長效化+天然結構"作用機理的長效生長激素。維昇藥業首席商務官陳軍在會上詳細拆解了TransCon技術平臺的突破:通過惰性載體(PEG)將天然結構的重組人生長激素暫時包裹和保護起來形成前藥,前藥在注射至皮下時沒有活性,進入血液迴圈在,將惰性載體與生長激素暫時連接起來的TransCon連接結構在體溫與生理pH值下發生自動裂解,7天內以特定的速率逐步釋放出與人體自身分泌完全一致的2.2萬道爾頓(22kD)、191個氨基酸的天然結構的生長激素。這一"暫時連接"機制與市面上其他長效生長激素的"永久連接"形成本質區別。陳軍指出,目前已上市的其他長效生長激素均屬於"生長激素類似物"——其活性分子結構已改變,分子量高達6萬-9萬道爾頓,遠遠高於天然生長激素的2.2萬道爾頓。維臻高(R)進入人體內釋放的活性分子與內源性生長激素的分子量、分子結構、組織分佈以及藥理特性相同,也是首款活性分子是"長效生長激素"而非"生長激素類似物"的長效產品。國婦嬰主任醫師餘文教授從臨床角度補充了關鍵細節:分子量過大的藥物難以穿透緻密的骨骺板,無法發揮生長激素的直接作用,也就可能直接影響療效。維臻高(R)以內源性生長激素的"原藥形式"發揮作用,是其頭對頭研究取得優效結果的理論依據和科學基礎。1.2 說明書上的"法律證據"餘文教授在交流中特別強調,在臨床實踐中,尤其是一款新藥,經國家藥監部門審評並寫入藥品說明書的內容,是判斷藥品療效與安全性的核心法定依據,也是臨床用藥的權威規範標準,它構成了療效與安全性判斷的核心標準,是藥品的"身份證"。維臻高(R)本次獲批的產品說明書直接顯示了其療效優於每日製劑:境外臨床研究結果:"主要療效終點是第52周時年化生長速率(AHV)。本品治療52周時的AHV非劣效並優效於健豪寧(R)組。此外,本品治療後的身高SDS較基線的增加幅度高於健豪寧(R)組。從治療第26周至第52周試驗結束時,對於AHV和身高SDS 較基線的變化,本品組都較健豪寧(R)組更顯著。"中國臨床研究結果:"主要療效終點是第52周AHV。本品治療52周的AHV為 10.66cm/年,相比諾澤(R)組的AHV 9.75cm/年,統計分析結果顯示達到非劣效性以及優效性,即證明了本品治療的52周AHV優效於諾澤(R)組,與境外3期研究結果一致。此外,本品組治療時的身高SDS較基線的增加幅度高於諾澤(R)組,也顯示了優效性。從治療第13周至第52周試驗結束時, 對於AHV和身高SDS較基線的變化,本品組都較諾澤(R)組更顯著。"1.3 安全性設計的雙重保障分子安全性:由於維臻高(R)的活性成分與內源性生長激素結構完全一致,避免了未知分子風險;而其他長效生長激素均為"人造分子",長期安全性存疑(輝瑞、諾和諾德曾嘗試PEG永久修飾技術研發長效生長激素,但均因安全性和療效問題終止研發)。局部安全性:注射部位無活性,避免脂肪萎縮等不良反應。陳軍特別解釋:其他部分長效產品將"7天劑量一次打入一個注射部位",注射部位存在高濃度活性成分;維臻高(R)的"包裹"技術使其在皮下無活性,只在該發揮作用時才呈現活性,降低了導致脂肪細胞溶解、皮膚凹陷的可能,這是"另一個安全性優勢"。更值得關注的是其長期安全性數據:維臻高(R)全球關鍵3期研究治療1年的結果顯示,其不良反應發生的種類與頻率均與生長激素日製劑相似;而在治療時間最長達6年的延長期研究中,維臻高(R)也未出現與生長激素日製劑不同的、新的不良反應類型。餘教授談到,生長激素日製劑在生長激素缺乏症患兒中已有超過40年的使用經驗,其安全性特已被臨床醫生熟知並掌握,基於明確的研究數據,維臻高(R)與日製劑一致的安全性表現,顯然也為醫生的應用提供了更充分的保障。1.4 儲存與使用的便利性突破維臻高(R)在不含防腐劑情況下,室溫(≤30℃)可儲存6個月,在2-8℃條件下可存儲5年,是唯一可在室溫下長期存放的生長激素。餘文教授強調:"這是我們當時完全沒有想到的效期,並且清楚的寫在說明書中。"這一特性對需要攜帶藥物出行、參加夏令營的家庭至關重要。1.5 注射體驗的創新設計維臻高(R)配備電子自動注射筆,由Phillips-Medisize公司生產,2022-2023年獲歐洲和美國三項工業設計大獎(PDA 藥物遞送創新獎、PharmaPack 給藥與包裝創新獎、紅點工業設計獎)。其特點包括:- 單按鈕開關,藥物複溶與注射全自動完成- 隱形針頭設計,患兒看不到針,減少心理恐懼- 配合固定劑量雙腔預充筆芯,注射前無需調節劑量,同時避免浪費- 每月4支筆芯+6支針頭的一體化包裝二、市場策略:技術與臨床優勢下的差異化商業路徑2.1 定價邏輯:突出產品差異化,以技術優勢形成產品價值優勢維昇藥業首席商務官陳軍表示:維臻高(R)的年治療費將會於產品上市時最終確定,但一定會顯著高於其他長效生長激素納入醫保後的價格。但這一定價並非簡單的"高端溢價",而是基於三重錨定:- 價值錨定:產品具備"天然結構+優效+室溫保存"三重獨特屬性,維臻高(R)作為長效生長激素迭代產品,產品的獨特優勢賦予了其核心定價權,將填補高端市場的真空。- 國際錨定:該產品在歐美獲批上市,美國年治療費用50-60萬元,維臻高(R)以其"技術優勢+臨床優勢+歐美品質"為背書,將臨床需求和價值錨點與國際接軌。- 長期健康價值錨定:生長激素治療具有明確的時間窗口和長期獲益特徵。其價值並不取決於單一年度的費用比較,而在於對終身身高結局、心理健康與社會功能的長期改善。從全週期視角衡量,該治療所帶來的健康收益與成本投入之間具有清晰、可解釋的價值邏輯。這一策略的風險在於支付能力,但維昇藥業的判斷是:生長激素市場90%以上為自費,80%以上銷售發生在私立醫院。2.2 管道佈局:合縱連橫的"作戰地圖"維昇藥業作為初創企業,選擇了"輕資產、重合作"的擴張路徑:- 推廣端:與安科生物強強聯手,其高級副總裁姚建平表示,公司在生長激素領域深耕27年,以學術觸達95%的生長激素KOL專家。此次與維昇藥業的合作,"27年經驗+劃時代產品"將形成前所未有的商業化佈局。雙方將按地域區隔運營,維昇藥業自營沿海核心市場,安科生物負責其餘廣闊區域,實現市場的全面覆蓋。- 流通端:上藥控股作為進口分銷平臺,依託其成熟的供應鏈體系,提供從通關到終端的全程服務。上藥控股副總經理宋潞潞指出,維臻高(R)是其經銷的大分子生物藥中,唯一不含防腐劑且可常溫保存6個月的產品,"這兩個優勢在對藥品商業化成功,特別是兒童用藥的商業化成功方面,至關重要"。- 診療端:與和睦家、小蘋果、卓正等高端私立醫院建立深度合作,構建"篩查-診療-管理"的全流程閉環。上海和睦家醫院長寧院區執行院長劉曉龍表示,其患者群體對"技術領先、長期安全"的產品需求明確,維臻高(R)的核心優勢與該群體需求高度匹配,具備良好的臨床土壤。- 流量端:患者及家庭在疾病認知與治療決策過程中,主要通過內容社區、AI 搜索工具及合規的互聯網醫療平臺獲取相關科普資訊,逐步形成以專業性、可及性和合規性為核心的患者資訊入口,讓優質醫療資訊精准觸達目標人群。三、團隊建設:用近乎苛刻的標準篩選最強執行者維昇藥業銷售與商業運營副總裁潘海風詳細介紹了團隊建設的"高強度、嚴標準"體系:- 招聘標準:一線商業化團隊中,約20%具備碩士學歷,80%為醫藥相關本科背景;近三分之一來自其他公司的地區經理級別,整體商業化人員結構和行業經驗顯著高於行業平均水準。- 考核機制:全員"日考+周考+月考",內容涵蓋產品知識、競品知識、臨床醫學、疾病知識;每日考試須達90分以上,集訓落地考不合格者原機遣返,以嚴苛的考核標準保障團隊的專業能力,確保用人標準與產品價值相一致。- 提前佈局:公司提前規劃、前置投入,產品上市前6個月商業化團隊已90%到崗,為產品上市後的快速市場推進做好了充分準備,體現出公司對商業化執行的前置投入與系統規劃。四、其他Q&A環節:問題一:在目前的定價水準下,維臻高(R)的利潤率表現如何?未來隨著地產化推進,盈利空間如何展望? 回答: 公司堅持"先上市、先可及"的策略,進口階段的毛利率足夠產品上市早期的推廣。隨著兩年多後實現地產化生產,即便在當前價格水準大幅下降的情況下,毛利率仍有望達到80%以上。從進口到地產化的路徑清晰,隨著市場規模的持續放量,盈利能力將隨規模放量持續改善。問題二:維臻高(R)在公立醫院與民營醫院中的銷售場景如何落地?在部分長效生長激素已進入國談的背景下,公司如何發揮差異化優勢? 回答: 公司將覆蓋三類管道:公立醫院院內、公立醫院處方外配及民營醫院。受國談因素影響,公立院內並非未來主戰場,核心增長將來自處方外配及民營醫療體系。同時,國家層面已明確提出要有序推進醫師多機構執業,鼓勵醫師依法開展多點執業,醫生在公立醫院與民營醫療機構之間的執業流動性持續提升。這一趨勢為創新、差異化產品在院外及民營場景中的推廣和規範使用創造了有利條件。公司將基於這一制度環境,在所有合規場景中積極佈局。問題三:除維臻高(R)外,公司其他管線在未來幾年的上市節奏及協同貢獻如何? 回答: 公司在內分泌領域已佈局多條管線,其中針對甲狀旁腺功能減退的帕羅培特立帕肽已分別於2024年年初和年底在歐盟跟美國獲批;第三個品種那韋培肽這個月底迎來其 PDUFA 日期,後續產品在中國的上市節奏有望加快。多產品協同放量後,公司整體規模有望持續躍升,長期目標是打造內分泌與代謝領域具備國際競爭力的百億級創新藥企。問題四:已使用短效生長激素的患者,是否可以無縫切換至維臻高(R)?是否有相關臨床證據支持? 回答: 國際3期試驗有一個關於日製劑轉換為隆培生長激素的研究。研究顯示,對於平均使用日製劑已有1.14年、平均劑量為0.29 mg/kg/周的患者,轉為隆培生長激素0.24mg/kg/周後,仍然保持了非常良好的追趕生長的趨勢。這一研究結果證明了由日製劑轉為隆培促生長素每週一次治療仍可保持非常良好的生長趨勢和療效。問題五:維臻高(R)在長期使用方面的療效和安全性表現如何? 回答: 在國際3期試驗的延長期實驗中,患者平均治療4.3年、最長達6年,期間患者身高持續改善,部分患者最終身高SDS甚至超過父母平均身高SDS,充分體現了產品在長期治療中的有效性、安全性及穩定性。問題六:公司目前商業化團隊建設情況如何?與安科生物的合作如何推進? 回答: 公司首年商業化團隊已基本到位,團隊人員以業內資深骨幹為主,強調高專業度、強培訓與嚴格考核。區域運營上,維昇負責沿海一線重點城市,安科覆蓋其他區域,雙方執行統一學術與培訓標準,形成"強強聯合"的銷售體系,共同推進產品的市場落地。五、長期展望:從單一產品到平臺價值維昇藥業執行董事兼首席執行官盧安邦在交流結束的致辭中描繪了公司長期發展的藍圖:維臻高(R)的獲批意味著TransCon技術平臺繼FDA和EMA後獲NMPA認可,為後續產品鋪平道路。在研的帕羅培特立帕肽(甲狀旁腺功能減退症)2024年美歐獲批後首年銷售近40億人民幣,那韋培肽(軟骨發育不全)針對中國1萬患兒的治療剛需。"2026-2028是公司"十年磨一劍"的決戰期,"盧安邦表示,"我們要驗證從臨床、註冊、准入到商業化的端到端能力,最終成為內分泌代謝領域的百億級領軍企業。"本文基於2026年2月2日維昇藥業投資者交流會紀要整理,內容僅供資訊參考,不構成投資建議。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CanSinoBIO’s Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential

HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by the National Medical Products Administration of China (the “NMPA”), pursuant to which, the supplemental application to expand the age range of applicable population of the Company’s Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the “MCV4”, trade name: Menhycia (R)) from “children aged from 3 months to 3 years old (47 months)” to “children aged from 3 months to 6 years old (83 months)” has been approved by NMPA.This approval marks an important step forward, underscoring the public health impact of Menhycia (R) while also strengthening its long-term commercial prospects. Under China’s current national immunization schedule, the final pre-school dose of meningococcal vaccination is administered at six years of age. For a long time, multivalent conjugate vaccine options for children over age three have been relatively limited in the domestic market. The newly approved expansion of the eligible age range helps address this gap, providing broader and more appropriate vaccination options for this population.At the same time, the broader eligible population is expected to further unlock Menhycia (R)’s commercialization prospects, and lay a more solid foundation for the product’s promotion and strategic rollout in international markets.Notably, CanSinoBIO issued its Results Forecast For The Year 2025 recently. Forecasting total revenue of RMB 1.04–1.08 billion, a year-on-year increase of 22.88% to 27.61% and net profit attributable to the shareholders of RMB 24.5–29.0 million—marking a return to profitability. The company noted that Menhycia (R), China’s first domestically developed quadrivalent meningococcal conjugate vaccine, continues to drive sustained revenue growth under its innovation-led commercialization strategy. This also signifies that the company is now reaping the commercial benefits of its early investments in vaccine innovation.Leveraging its proprietary platform, first-mover advantages, and accelerating global expansion, the age expansion of Menhycia (R) is expected to further strengthen CanSinoBIO’s competitive position while providing new momentum for sustainable growth. As product coverage broadens and international commercialization advances, the company is well-positioned to enter a new phase of long-term growth. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Shoucheng Holdings (00697.HK) Sees Long-Term International Capital Rotation as Robotics Portfolio Enters Harvest Phase

HONG KONG, Feb 25, 2026 - (ACN Newswire via SeaPRwire.com) – Shoucheng Holdings Ltd. (00697.HK) drew market attention on Tuesday after its share price experienced volatility alongside certain shareholding adjustments, prompting discussion among investors. A review of the company’s recent disclosures, publicly available trading data and evolving market structure suggests the movement largely reflects short-term capital repositioning rather than any change in fundamentals.Market participants indicated that during the recent market pullback, several international long-only investors executed strategic allocations through block trades and negotiated transactions, facilitating an orderly transition in the company’s shareholder base. Observers said the shift — characterized by a rotation from short-term trading positions to longer-duration institutional capital — could help smooth liquidity fluctuations while enhancing the stability and quality of the shareholder structure.From a capital-markets perspective, the entry of long-term funds typically signals recognition of a company’s medium- to long-term growth trajectory and value realization capacity. Such positioning is widely viewed as laying a firmer foundation for future valuation normalization.Historically, shareholder base optimization and rebalancing often coincide with the stage at which a company’s strategic transformation begins to translate into tangible results. The latest restructuring underscores a more proactive stance by international capital in participating in Shoucheng’s growth story, endorsing its strategic shift from a traditional asset-management platform to a builder of hard-technology industrial ecosystems. The resonance between capital flows and industrial logic is expected to reinforce market confidence in the company’s long-term value proposition.Foreign institutional buying during periods of market weakness reflects confidence in what analysts describe as a structural transformation of Shoucheng’s fundamentals. The company has transitioned from a conventional asset-management model into what it terms an “industrial ecosystem builder.” Through a differentiated “capital + scenario + operations” framework, Shoucheng has established a closed-loop ecosystem, particularly in the robotics sector, where its forward-looking investments have positioned it as a bellwether for hard-technology exposure in Hong Kong equities.The year 2026 is widely regarded by the market as a pivotal window for the accelerated commercialization of embodied artificial intelligence and humanoid robotics. Shoucheng’s systematic early-stage positioning across the robotics value chain is now entering a concentrated realization phase, with portfolio returns demonstrating notable strength.Core projects have generated substantial premiums. Early and concentrated investments in leading companies such as Zibianliang Technology and Unitree Robotics have delivered significant mark-to-market gains. As high-profile holdings including Unitree advance toward initial public offerings, Shoucheng’s equity stakes are poised to transition from unrealized book gains to realized returns and dividend contributions, providing tangible earnings accretion at the listed-company level.Further attention has focused on the high-profile appearance of robotics firms including Unitree Robotics, Galaxy General Robotics and Songyan Dynamics at the 2026 Lunar New Year Gala broadcast by China Central Television, the Year of the Horse edition. Their demonstrations showcased breakthroughs in embodied intelligence, complex motion control and human-machine interaction. The visibility not only strengthened public awareness but also signaled that large-scale commercial deployment may be imminent. As an important early-stage investor in these enterprises, Shoucheng stands to benefit indirectly from both heightened sector visibility and an accelerated commercialization cycle, potentially catalyzing valuation re-rating.Analysts said Tuesday’s trading activity is likely to result in a more diversified shareholder mix. The participation of long-duration international capital may enhance the stock’s global liquidity profile and governance transparency expectations, while also broadening the company’s access to cross-border industrial and strategic resources to support future expansion.Market experience suggests that when a company’s fundamentals enter an upward cycle and structural uncertainties gradually dissipate, shareholder optimization can serve as a catalyst for valuation recovery. According to analysts, the latest rotation in holdings represents a strategic rebalancing of the capital structure, easing short-term supply pressure as the company approaches a value-realization phase.Taken together, Shoucheng appears to be navigating a convergence of three inflection points. First is an industrial inflection, as embodied AI and robotics commercialization accelerate. Second is a capital inflection, with investment projects entering a concentrated realization period. Third is a structural inflection, marked by the entry of long-term international capital and the optimization of the shareholder base.Amid the alignment of global capital endorsement and industrial value dividends, the company’s valuation framework is shifting from that of a traditional asset manager toward that of a hard-technology industrial platform. As industrial deployment advances and investment returns crystallize, market recognition of Shoucheng’s role as an infrastructure builder for the intelligent era may deepen, suggesting that the process of long-term value redefinition has entered a substantive phase. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

首程控股(00697.HK)迎來國際長線接盤 機器人產業生態進入價值收割期

香港, 2026年2月25日 - (亞太商訊 via SeaPRwire.com) - 今日,市場關注到首程控股(00697.HK)股價出現一定波動,疊加個別股份變動安排,引發部分投資者討論。綜合公司近期公告、公開行情數據及市場結構變化情況來看,相關波動更多體現為階段性資金博弈。在資本結構持續優化、產業主線邏輯清晰的背景下,公司基本面未發生實質性變化。市場人士透露,在近期市場調整過程中,部分國際長線資金通過協議及大宗方式完成戰略性布局,實現了籌碼結構的有序轉換。相關觀點認為,這種「短期籌碼向長期資本轉移」的過程,有助於平滑階段性流動性波動,同時提升股東結構的穩定性與質量。從資金屬性看,長線資本的進入往往意味著對公司中長期成長路徑與價值兌現能力的認可,為後續估值修復奠定更加堅實的資金基礎。從資本市場運行規律來看,當企業戰略轉型逐步進入成果兌現階段時,股東結構的優化與再平衡往往同步發生。本輪結構調整所釋放的核心信號在於,國際資金正以更為積極的姿態參與公司成長進程,認可其由傳統資產管理平台向「硬科技產業生態構建者」升級的戰略方向。這種資本與產業邏輯的共振,有助於強化市場對公司長期價值的認知與定價信心。外資機構的逆勢買入,其邏輯支撐源於首程控股基本面的深刻蛻變。公司正從傳統的資產管理平台,成功向「產業生態構建者」轉型。通過獨特的「資本 + 場景 + 運營」三維模式,首程控股已構建起閉環生態,特別是在機器人賽道的前瞻性布局,已使其成為港股硬科技投資的標杆。2026年被市場普遍視為具身智能與人形機器人商業化加速落地的重要時間窗口。首程控股前期在機器人賽道的系統性布局,正在進入集中收穫期,機器人賽道整體投資回報表現亮眼:核心項目實現高溢價。依托對自變量科技、宇樹科技等領軍企業的早期重倉,已實現顯著帳面增值。隨著宇樹科技等明星項目正式開啟IPO衝刺,首程控股持有的股權將迎來從「帳面浮盈」向「現金分紅」的實質性跨越,持續增厚上市公司利潤。此外,值得關注的是,在2026年馬年央視春晚舞台上,宇樹科技、銀河通用、松延動力等機器人企業集體亮相,展示了具身智能技術在複雜動作控制與人機交互方面的突破。這不僅強化了公眾認知,也標誌著相關企業已進入規模化應用前夜。作為上述企業的重要早期布局方,首程控股間接受益於產業熱度與商業化進程提速帶來的估值重估。市場分析人士表示,今日的市場交易將促使公司股東結構更趨多元化。國際長線資金的進入,一方面提升了股票的全球流動性基礎與治理透明度預期,另一方面也為未來產業擴張提供更廣泛的資源協同空間。從市場經驗看,當企業基本面處於上行周期且結構性不確定性逐步消除時,股東結構的優化往往成為估值修復的重要觸發因素。分析人士指出,本輪籌碼調整本質上是資本結構的戰略再平衡,為公司進入價值兌現周期掃清短期供給壓力。綜合來看,首程控股當前處於三重拐點疊加階段。首先是產業拐點——具身智能與機器人商業化加速;其次是資本拐點——投資項目進入集中兌現期;再次是結構拐點——國際長線資本入場優化股東結構。在國際資金認可與產業價值紅利共振之下,公司估值邏輯正從「傳統資管估值框架」向「硬科技產業平台估值框架」切換。隨著產業落地與資本回報逐步兌現,市場對於首程控股作為「智能時代產業基礎設施構建者」的認知將進一步強化,其長期價值重塑進程或已進入實質性階段。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

國泰君安國際獲批使用SIMM 衍生品風險管理接軌國際標準

香港, 2026年2月25日 - (亞太商訊 via SeaPRwire.com) - 2月23日,國泰海通集團下屬公司國泰君安國際控股有限公司(「國泰君安國際」或「公司」,股份代號:1788.HK))宣布,已正式獲得香港證券及期貨事務監察委員會(SFC)批准,自2026年2月12日起可在其兩家持牌機構(國泰君安證券(香港)有限公司及國泰君安外匯有限公司)采用國際掉期與衍生工具協會ISDA標準初始保證金模型(Standard Initial Margin Model, "SIMM" )計算場外衍生品交易的初始保證金。ISDA SIMM 是業界通用的標準方法論,專門用于計算非集中清算衍生品的監管初始保證金。該模型通過建立統一的計算標準,使所有市場參與者得以遵循同一框架進行保證金核算,不僅避免了各機構獨立開發模型所産生的額外成本,還有效减少了因算法差异引發的潜在爭議。其配套的治理框架進一步確立了行業共同實踐,確保保證金計提既符合全球監管要求,又充分保障了保證金的充足性。此次獲批標志著國泰君安國際場外衍生品業務的風險管理能力邁上新台階,在鞏固合規與風控標杆的同時,顯著提升中資券商國際化競爭力。通過采用國際市場通行的SIMM模型,公司得以接軌國際大行標準,能够更精准、高效地管理初始保證金,在有效控制交易對手風險的同時,顯著節省交易成本,實現更高資本效率,增强與全球機構對手方的合作信任,從而提升業務的長期競爭力。此次獲批不僅是對公司衍生品業務技術實力的認可,更是監管機構對公司內部控制、尤其是風險管理能力的又一里程碑式肯定。展望未來,國泰君安國際將進一步精進衍生品業務的內控管理體系,築牢長遠穩定發展的根基。同時,作爲香港資本市場的重要一員,公司將一如既往地配合監管機構,深度參與市場基礎設施建設,助力提升香港場外衍生工具市場的國際競爭力與活力。關於國泰君安國際國泰海通集團下屬公司國泰君安國際(股票代號:1788.HK),是中國證券公司國際化的先行者和引領者,公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港爲業務基地,幷在新加坡、越南和澳門設立子公司,業務覆蓋全球主要市場,爲客戶境外資産配置提供高品質、多元化的綜合性金融服務,核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前,國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級,MSCI ESG「A」評級, Wind ESG「A」評級及商道融綠ESG「A」評級,同時其標普全球ESG評分領先全球81%同業。公司控股股東國泰海通證券(股票代號:601211.SH/2611.HK)爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China

SHENZHEN, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product's review process for marketing approval in the AD indication.Impressive phase III trial data in ADIts Priority Review is expected to accelerate its NDA approvalRuxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product's expansion into multiple therapeutic areas.Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD.Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated.Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date.Building an integrated AD solution,strengthening Dermavon’s leadership in dermatologyAD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care.Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's market competitiveness and brand influence in the field of skin health.More Information About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurarCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

康哲藥業(867.HK/8A8.SG):創新藥磷酸蘆可替尼乳膏增加特應性皮炎(AD)適應症中國上市許可申請獲受理並獲納入優先審評

深圳, 2026年2月24日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司 (「康哲藥業」)欣然宣佈,旗下德鎂醫藥有限公司(「德鎂醫藥」,專業聚焦皮膚健康的創新型醫藥企業,正申請於香港聯合交易所有限公司主板獨立上市,詳見康哲藥業日期為2025年4月22日發佈的公告)已於2026年2月24日獲得中國國家藥品監督管理局(NMPA)受理磷酸蘆可替尼乳膏(「產品」)輕中度特應性皮炎(「AD」)的新藥上市許可申請(NDA)。產品擬用於其他外用藥控制不佳或不建議使用時,非免疫功能受損的2歲及以上兒童和成人輕中度特應性皮炎的局部短期和非持續性慢性治療。且該項NDA因「符合兒童生理特徵的兒童用藥品新品種、劑型和規格」,已獲得NMPA藥品審評中心批准納入優先審評品種名單,有望加快產品AD適應症上市審評進程。特應性皮炎III期臨床數據亮眼,優先審評加速上市磷酸蘆可替尼乳膏已於2026年1月獲得NMPA批准上市,成爲中國批准的首款且唯一用於白癜風治療的靶向藥。此次增加AD適應症NDA獲受理,是產品向多治療領域拓展的關鍵里程碑。磷酸蘆可替尼乳膏已在輕中度AD的一項隨機、雙盲、安慰劑對照中國三期藥物臨床研究取得積極結果:- 療效優異:產品成功達到主要終點,即使用產品治療8周,達到研究者整體評估(IGA)評分為0或1分,且較基線改善≥2分的受試者比例,顯著高於安慰劑(63.0% vs 9.2%,P<0.001)。關鍵次要終點,磷酸蘆可替尼乳膏治療8周,達到濕疹面積及嚴重程度指數評分較基線至少改善75%(EASI 75)的受試者比例亦顯著優於安慰劑(78.0% vs 15.4%,P<0.001)。- 安全性良好:治療期出現的不良事件(TEAE)的嚴重程度大多數為輕度或中度,未發生導致研究藥物用藥終止的TEAE,整體安全耐受性良好。此外,該項NDA已獲批納入優先審評品種名單。根據NMPA相關規定,適用優先審評審批程序的上市註冊申請的審評時限由常規程序的200日大幅縮短爲130日,審評時限將得到顯著縮短,這將有望加速磷酸蘆可替尼乳膏AD適應症的上市進程,早日惠及廣大患者。構建特應性皮炎綜合方案,強化皮膚領域競爭實力AD是一種慢性、復發性、炎症性的皮膚疾病,臨床主要表現為皮膚乾燥、慢性濕疹樣皮損和明顯瘙癢,可能嚴重影響患者的生活品質。據估算,2024年中國特應性皮炎患者超過5,400萬人,基於SCORAD評分,輕中度特應性皮炎的占比為98%,即超過5,250萬患者[1]。外用藥物是AD最基本的治療方法。傳統外用藥物如外用糖皮質激素(TCS)及外用鈣調神經磷酸酶抑制劑(TCIs)有長期用藥的不良反應或療效有限的臨床痛點,臨床亟需新的治療選擇。德鎂醫藥已針對AD構建了全方位的「治療+護理」綜合解決方案,除局部外用製劑-磷酸蘆可替尼乳膏(輕中度AD)外,還包括注射用生物製劑-柯美奇拜單抗注射液-MG-K10(中重度AD)、口服小分子靶向藥-CMS-D001(中重度AD)、日常修護-禾零舒緩產品系列,滿足AD患者從治療到日常護理的管理需求。同時,此次增加AD適應症NDA獲受理,將進一步強化德鎂醫藥在皮膚治療領域的戰略佈局,並與現有處於商業化階段的創新藥益路取(替瑞奇珠單抗注射液)、獨家藥喜遼妥(多磺酸粘多糖乳膏),以及系列在研創新藥和皮膚學級護膚品等在專家網絡與市場資源等方面產生協同,提升德鎂醫藥在皮膚健康領域的市場競爭力與品牌影響力。關於磷酸蘆可替尼乳膏的更多信息磷酸蘆可替尼乳膏(Opzelura(R))是Incyte開發的選擇性JAK1/JAK2抑制劑蘆可替尼製成的一種創新型乳膏。在中國,磷酸蘆可替尼乳膏獲批用於治療12歲及以上兒童和成人患者伴面部受累的非節段型白癜風。在美國,磷酸蘆可替尼乳膏是經美國食品和藥物管理局(FDA)批准的首款局部JAK抑制剂,可用於局部治療12歲及以上患者的非節段型白癜風;及其他外用藥控制不佳或不建議使用時,非免疫功能受損的2歲及以上兒童和成人輕中度特應性皮炎的局部短期和非連續性慢性治療[2]。在歐洲,磷酸蘆可替尼乳膏被批准用於治療成年及12歲及以上青少年面部受累的非節段型白癜風[3]。康哲藥業於2022年12月2日,通過德鎂醫藥的附屬公司與Incyte就磷酸蘆可替尼乳膏訂立合作和許可協議(「許可協議」),獲得在中國大陸、香港特別行政區、澳門特別行政區、臺灣地區及東南亞十一囯(「區域」)研發、注冊及商業化產品的獨家許可權利,以及在區域內生產產品的非獨家許可權利。德鎂醫藥的附屬公司已將磷酸蘆可替尼乳膏除中國大陸外的其他區域的相關權利再許可予康哲藥業(不包括德鎂醫藥及其附屬公司)。Incyte擁有磷酸蘆可替尼乳膏全球開發和商業化權利,在美國及歐洲以Opzelura(R)的名稱銷售。Opzelura(R)和Opzelura(R)標識是Incyte的註冊商標。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化,把控產品全生命週期管理的開放式平臺型企業,致力於提供有競爭力的產品和服務,滿足尚未滿足的醫療需求。康哲藥業專注於全球首創(FIC)及同類最優(BIC)的創新產品,並高效推進創新產品臨床研究開發和商業化進程,賦能科研成果向診療實踐的持續轉化,造福患者。康哲藥業聚焦專科領域,擁有被驗證的商業化能力,廣泛的渠道覆蓋和多疾病領域專家資源,核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展,以鞏固心腦血管/消化/眼科/皮膚健康業務競爭力,帶來專科規模效率,其中皮膚健康業務(德鎂醫藥)已成為其細分領域的龍頭企業,並擬於聯交所獨立上市。同時,康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展,以獲取新興市場的增量,助力集團實現高質量可持續發展。參考文獻/資料1.數據來自灼識諮詢報告2.FDA批准信息可在Incyte官網查詢,網址:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3.EMA批准信息可在Incyte官網查詢,網址:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣,非廣告用途。本新聞不對任何藥品和-醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療資訊,請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請,不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制,但康哲藥業並無進行任何說明或保證、明述或暗示,或其他表述,對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述,該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證,存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測,康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

康希諾生物曼海欣(R)擴齡正式獲批 為公司長期價值開啟更廣闊發展空間

香港, 2026年2月24日 - (亞太商訊 via SeaPRwire.com) - 康希諾生物(688185.SH/06185.HK)宣佈,公司自主研發的ACYW135群腦膜炎球菌多糖結合疫苗(CRM197載體)——曼海欣(R)擴大適用人群的補充申請已正式獲得國家藥品監督管理局批准。此次獲批後,曼海欣(R)適用於3月齡至6周歲(83月齡)的嬰幼兒及兒童,用於預防由A、C、Y、W135群腦膜炎奈瑟菌引起的流行性腦脊髓膜炎(以下簡稱"流腦")。此次曼海欣(R)擴齡獲批,具有重要的公共衛生和商業發展意義。一方面,在我國現行免疫規劃程式中,6歲是入學前流腦疫苗接種"最後一針"的重要節點,長期以來,國內針對3歲以上兒童的多價流腦結合疫苗選擇相對有限。曼海欣(R)此次擴齡獲批,為學齡期兒童提供了四價流腦多糖結合疫苗接種選擇,有助於填補兒童流腦防控在關鍵年齡階段的保護空白,進一步完善我國流腦免疫屏障。另一方面,適用人群範圍的擴大,將有助於曼海欣(R)進一步釋放產品潛力,提升商業化空間,並為該產品在國際市場的推廣與佈局奠定更為堅實的基礎。值得一提的是,康希諾生物日前已發佈2025年度業績預告,全年營收預計10.4–10.8億元,同比增長22.88%-27.61%;歸母淨利潤預計2450萬–2900萬元,將實現扭虧為盈。同時,公告明確指出,"公司持續踐行以創新為核心、以商業化落地為重點的發展戰略,中國首款四價流腦結合疫苗曼海欣(R)收入保持持續增長"。這也意味著康希諾生物已進入創新疫苗商業化收穫期。依託獨家技術平台、領先優勢及加速的國際化佈局,曼海欣(R)擴齡不僅鞏固了市場競爭力,也為康希諾生物的可持續增長注入新的動力。隨著產品覆蓋和國際拓展的推進,公司長期價值將開啟更廣闊的發展空間。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

迦里仕人才與耐吉澳門分公司續簽五年戰略合作協議 深化長期夥伴關系 夯實高端客戶基本盤

香港, 2026年2月24日 - (亞太商訊 via SeaPRwire.com) - 2026年2月22日, 納斯達克上市公司迦里仕人才集團有限公司(Galaxy Payroll Group Limited,NASDAQ: GLXG,以下簡稱「迦里仕人才」)今日宣布,已與耐吉中國控股香港有限公司澳門分公司(NIKE China Holding HK Limited (Macau Branch),以下簡稱「耐吉澳門分公司」)正式續簽為期五年的戰略合作協議。合作再延五年,服務範圍全面覆蓋核心HR職能根據協議,雙方合作期限自2025年12月1日起至2030年11月30日止。在此期間,迦里仕人才將繼續為耐吉澳門分公司提供涵蓋本地薪資發放、考勤與休假管理、社保及稅務合規申報,以及勞動法規與用工政策咨詢在內的一站式人力資源外包服務。該合作模式有效支持耐吉澳門分公司聚焦其核心零售與品牌運營,提升整體組織效能。戰略續約彰顯客戶高度信任,強化收入穩定性此次續約不僅是雙方合作關系邁入新階段的重要標志,更體現了國際頭部品牌對迦里仕人才專業能力、合規水平及長期服務交付質量的高度認可。中長期合約的簽署顯著增強了公司未來五年收入的可預測性與現金流穩定性,進一步契合其打造高質量、抗周期業務模型的資本市場戰略。本地化能力構築核心壁壘,服務體系持續進化自2013年成立以來,迦里仕人才始終深耕港澳市場,並逐步拓展跨區域服務能力。公司憑借對香港及澳門勞動法、稅務及社保政策的深度掌握,建立起紮實的本地合規能力;同時依托標准化流程與定制化方案相結合的服務體系,確保交付的一致性與可擴展性。其自主開發的薪資與考勤管理平臺,在提升運營效率的同時有效保障數據安全與業務連續性,成為吸引並維系跨國企業客戶的關鍵優勢。在過往合作中,迦里仕人才已多次協助耐吉澳門分公司應對複雜用工環境下的合規挑戰,其解決方案在准確性、響應速度及風險控制方面均獲得充分驗證,為本次長期續約奠定了堅實基礎。展望未來:從服務交付邁向價值共創展望新合作周期,迦里仕人才將在現有服務框架基礎上,持續優化薪資管理流程與智能考勤系統,並通過數據整合與定期管理報表,助力客戶推進人力資源管理的規範化與數字化轉型。雙方亦約定保留通過補充協議靈活拓展服務範圍的機制,確保合作節奏與客戶業務發展動態同步。此次五年期戰略合作的續簽,不僅是對迦里仕人才專業價值的長期肯定,更是對其商業模式可持續性的有力印證。它將進一步鞏固公司在港澳及亞太人力資源外包市場的品牌影響力,並為服務更多跨國零售、體育及消費品牌提供可複制的標杆案例。在全球企業日益重視合規效率、成本優化與組織韌性的背景下,迦里仕人才正憑借其深厚的本地化經驗、穩健的服務體系與高粘性的優質客戶基礎,穩步構建長期增長動能。公司管理層表示:「我們將繼續以服務能力為核心驅動力,深化與現有優質客戶的戰略合作,同時積極拓展更多具有長期價值的跨國及區域性企業客戶,持續為股東創造穩健、可持續的回報。」 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

五一視界x摩爾線程:新一代仿真與GPU完成適配 共築全棧國產化物理AI底座

香港, 2026年2月24日 - (亞太商訊 via SeaPRwire.com) – 2026年新版《道路機動車輛生產企業准入審查要求》中,仿真驗證能力被作為強制性關鍵要素寫入准入審查要求,國產仿真平臺迎來巨大的市場利好,進一步推動了智駕產業鏈加速向「自主可控」邁進。在此背景下,五一視界宣布旗下51Sim下一代智駕仿真平臺 SimOne 4.0 已於近日成功完成在摩爾線程旗艦級AI訓推一體全功能GPU MTT S5000上的系統性適配與深度優化。從大模型感知挖掘、4DGS模型訓練到4DGS仿真推理和合成數據生成,雙方強強聯手,實現了國產算力與端到端智能駕駛仿真體系的完整打通,正式開啟了物理AI智駕領域高置信度閉環仿真與合成數據的全棧國產化新篇章,為應對新規下的嚴苛驗證需求提供了堅實的國產底座。算力底座的「跨代式」追趕隨著端到端智駕收斂到VLA和世界模型兩條路線,基於海量Log數據的高置信度閉環仿真和合成數據已成為提升算法長尾場景處理能力的關鍵命題。仿真效率的上限,往往取決於基礎一硬件的規格。在很長一段時間裏,高端GPU市場幾乎被海外巨頭壟斷,但五一視界與摩爾線程的最新合作成果顯示,這一格局正在發生微妙的變化。SimOne 4.0已完成與摩爾線程MTT S5000的深度適配。MTT S5000是專為大模型訓練、推理及高性能計算而設計的全功能GPU智算卡,基於第四代MUSA架構「平湖」打造。其單卡AI算力(稠密)最高可達1000 TFLOPS,配備80GB顯存,顯存帶寬達到1.6TB/s,卡間互聯帶寬為784GB/s,完整支持從FP8到FP64的全精度計算。基於SimOne 4.0實現7個周視攝像頭4DGS場景重建效果在實測數據中,MTT S5000展現出了足以抗衡甚至部分超越國際主流競品的硬實力。數據顯示,MTT S5000在FP32、FP16及INT8等關鍵精度上實現了約1.47倍的性能增長,FP64雙精度算力領先幅度約1.48倍。更值得關注的是其搭載的MTLink技術,使得卡間帶寬提升約30%。MTT S5000憑借FP8提升訓推效率、FP64保障計算精准、光線追蹤實現高保真渲染,以自主可控的強勁底層算力,為智能駕駛提供安全、高效、可靠的核心國產算力支撐。場景實測:在複雜博弈中驗證「真功夫」硬件參數的領先,最終需要在真實的算法場景中落地。在SimOne 4.0的大模型感知挖掘功能中,雙方針對Qwen3-VL多模態大模型進行了深度調優。實測結果令人驚喜:無論是在8B模型還是更複雜的30B MoE架構下,MTT S5000在「預填充(Prefill)」階段的首字響應速度(TTFT)均優於國際主流競品,優勢最高擴大至14%,且在10並發的高壓環境下依然保持了穩健的吞吐量。而在更考驗訓練和推理能力的4DGS(4D高斯潑濺)領域,基於51Sim入選AAAI 2026的LidarPainter技術,國產算力同樣經受住了考驗。目前測試數據顯示,在訓練端,MTT S5000展現出比肩國際主流競品的強勁性能,僅需2.5小時即可完成一個真實Clip場景的高質量重建;在推理端,面對單Clip包含1600萬個高斯點的超大模型負載,MTT S5000成功實現了11路攝像頭加1路激光雷達的實時閉環仿真,呈現出像素級的高保真效果。這證明了國產顯卡在處理複雜光影與動態物體還原時,已經具備了生產力級別的屬性,能夠勝任准入審查中要求的極端工況與邊界條件驗證。這種高保真物理場景的重建能力,同樣可遷移至具身智能機器人的空間感知與操作訓練中。基於LidarPainter 技術生成高真實度新視角圖像隱形護城河:構建「芯片+系統」的通用底座如果說高性能GPU的適配是攻克了「最難的骨頭」,那麼對國產基礎軟硬件生態的全面覆蓋,則是五一視界構築的一條安全護城河,也是響應國家信創戰略、滿足敏感行業准入要求的關鍵。除了圖形計算領域,五一視界已悄然完成了對主流國產芯片架構的全線互認。在CPU層面,無論是基於ARM架構的華為鯤鵬、飛騰,還是基於x86架構的海光、兆芯,五一視界旗下的51Aes、51Sim等核心產品均已實現流暢部署。特別是通過華為鯤鵬技術認證並加入「鯤鵬展翅」計劃,進一步夯實了其在國產服務器端的運行穩定性。在操作系統層面,為了徹底擺脫對非國產發行版的依賴,五一視界將適配工作下沉至系統內核,先後完成了與麒麟軟件(銀河麒麟高級服務器操作系統)及統信軟件(UOS)的適配認證。這一舉措意味著,對於政府、能源等有著嚴苛信創要求的敏感行業客戶而言,他們可以選擇從芯片到底層操作系統到上層應用全鏈路自主可控的數字孿生解決方案,從容應對日益嚴格的合規性審查,構建起一個不僅服務於智能駕駛,更能廣泛賦能於人形機器人等具身智能終端的國產化通用基礎設施。中國科技企業「國產自主可控」已經崛起從攜手摩爾線程在高端算力上撕開缺口,到打通華為鯤鵬、麒麟等操作系統的生態脈絡,再到積極響應新版准入審查要求提供合規的仿真驗證能力,五一視界的這一系列動作表明,中國企業的「國產自主可控」正在發生量變和質變,正在緩緩崛起。這不再是簡單的參數對標,而是產業生態的戰略閉環。SimOne 4.0的表現證明,國產軟硬件方案已經邁過了「能用」的門檻,正式進入了高精度、高負載任務的「好用」階段。隨著算法與算力的深度融合,以及政策法規對仿真驗證能力的強制加持,一個繁榮的、自主可控的物理AI生態底座正在逐步成型,為中國智能駕駛產業的獨立發展保駕護航,也為具身智能機器人等新興領域的國產化落地鋪平了道路。基於SimOne 4.0 的4DGS閉環仿真 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

滬港新興產業基石基金在港正式開業

香港, 2026年2月24日 - (亞太商訊 via SeaPRwire.com)  – 2月23日,由上海實業(集團)有限公司(以下簡稱「上實集團」)與國泰海通證券股份有限公司(以下簡稱「國泰海通」)聯合發起設立的滬港新興產業基石基金(以下簡稱「基石基金」)正式啟航,進入實質投資階段。作為全國首支、上海市級市場化運作的證券類港股基石基金,基金目標總規模30億港元,首期規模10億港元,將聚焦集成電路、生物醫藥、人工智能上海三大先導產業,專項支援優質企業赴港上市,深化滬港金融與產業協同。服務上海戰略,強化滬港聯動上海市政府和上海市國資委指導設立的基石基金,是上海國資服務上海科技創新中心建設、推動重點產業高質量發展的重要舉措,將緊密圍繞上海前瞻的集成電路、生物醫藥、人工智能三大先導產業進行戰略佈局,通過資本市場賦能,加速本地創新企業國際化進程。同時,基金也將充分發揮香港作為國際金融中心的樞紐功能,構建「上海產業+香港資本」的高效聯通機制,促進兩地金融資源互補與市場互聯,打造滬港合作新標杆。創新「雙管理人」架構,滙聚兩地專業力量基石基金在治理模式上採用創新的「雙管理人」架構,由上實集團在港金融投資業務平台上實資本(香港)投資管理有限公司,和國泰海通在港資產管理平台海通國際資產管理有限公司共同擔任基金管理人,並由滬港兩地協同運營。這一合作架構充分融合了上實集團作為上海在港窗口企業的產業資源與香港本地的運營優勢,及國泰海通在全球資本市場和跨境資產管理方面的專業能力,實現「產業+金融」、「上海+香港」的雙重優勢互補。通過建立完善的投資決策機制與風險控制體系,該架構既確保了基金運作符合國際標準,又保持了與本土產業生態的深度連結,為基金的長期穩健運作奠定了堅實基礎。多元化投資策略,專注長期價值基石基金堅持市場化、專業化、國際化運作原則,以產業、金融雙重視角,構建覆蓋企業全生命週期的投資與賦能體系。通過靈活的多元化策略組合與深度投後服務,系統性支援上海三大先導產業優質企業的業務發展與價值實現。基石基金在重點參與上海三大先導產業優質企業赴港IPO的基石投資之外,還可以參與港股IPO錨定和已上市港股的配售投資,通過無鎖定期策略保持基金的流動性,以保證基金投資收益;在市場大幅下跌時,也可通過二級市場方式,增持價值低估的優質公司股票;同時跟進優秀企業再融資及併購重組,助力可持續發展。基石基金將嚴格遵循「好賽道、好公司、好價格」的遴選標準,重點投向具備核心技術、高成長性和穩健現金流的行業領軍企業。強化上海國資在港功能,構建跨境投資新平台基石基金是上實集團和國泰海通強化在港服務功能、完善跨境投資佈局的關鍵舉措之一。基石基金不僅進一步完善上海國資基金矩陣,填補國資基金在港股IPO及二級市場策略的空白,服務上海企業赴港上市「最後一公里」融資需求,助力構建「早期投資—成長期融資—公開市場上市」的完整產業投資生態;更通過上實集團和國泰海通的深度合作,強強聯手、協作共贏,系統提升跨境合規、資產配置與複雜交易設計能力,進一步增強上海國資服務上海乃至國家戰略的綜合實力。展望:鏈接國際資本,賦能創新未來在全球科技創新競爭日益激烈的背景下,滬港新興產業基石基金的實質啟動,標誌著上海在對接國際資本市場、服務本土創新方面邁出系統性的一步。在人民幣國際化和「惠港五條」等政策紅利支持下,基石基金將成為連接內地產業資本與國際金融資源的重要紐帶。未來,基石基金將積極把握人民幣國際化與金融市場雙向開放機遇,持續促進國際資本投資上海核心產業,為上海三大先導產業企業提供全方位的資本服務,助力更多硬科技企業走向世界,為滬港融合與高質量發展貢獻力量。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

GA-ASI Announces YFQ-42A Dark Merlin

SAN DIEGO, Feb 23, 2026 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA-ASI) is giving its U.S. Air Force Collaborative Combat Aircraft a new name: YFQ-42A Dark Merlin.Dark merlins, deadly falcons known for their black feathers and devouring of other falcons as prey, often collaborate in groups for maximum effect against their targets. The Cornell Lab of Ornithology describes the merlin as a "small, fierce falcon that uses surprise attacks" to bring down its prey in flight. The dark merlin is native to the Pacific Northwest of the United States, often migrating into southern California, where bird spotters routinely report seeing them near the YFQ-42A's manufacturing home in San Diego.The 1962 book "Profiles of the Future" imagined global technological marvels yet to change the world, offering that "any sufficiently advanced technology is indistinguishable from magic." It's no coincidence that the Dark Merlin name also reflects the wizardry of Merlin from Arthurian legend, paying homage to the somewhat supernatural new era of semi-autonomous air combat."Dark merlins are hunting machines, built for speed and aerodynamics," said GA-ASI President David R. Alexander. "They harass other falcons for fun, and they eat what they kill. The name sums up our new uncrewed fighter perfectly."The U.S. Air Force official prefix "Y" denotes that the initial few aircraft are early, production-representative test models, while "F" denotes fighter and "Q" denotes uncrewed aircraft. When aircraft enter production, they drop the "Y" - for example, the YF-16 became the F-16 with the nickname "Fighting Falcon" - and GA-ASI expects its new CCA to become the FQ-42A with the nickname "Dark Merlin."The Dark Merlin has been stacking up milestones and achievements since GA-ASI was selected by the U.S. Air Force in April 2024 to build production-representative flight test articles for the CCA program. In August 2025, YFQ-42A delivered the U.S. Air Force its first successful CCA flight and followed that this month with the service's first CCA flight using mission autonomy software. Between those milestones, GA-ASI has built and flown multiple Dark Merlins, conducting push-button autonomous takeoffs and landings and other accomplishments as the test program continues.YFQ-42A Dark Merlin is a purpose-built CCA platform developed as part of GA-ASI's ongoing investment in next-generation autonomous combat aircraft. The aircraft's modular design enables rapid integration of mission systems. GA-ASI's autonomy architecture, demonstrated through multiple live flight tests, provides the foundation for human-machine teaming in complex combat scenarios.GA-ASI has been building and flying uncrewed jets for nearly two decades, beginning with the company-funded, weaponized MQ-20 Avenger® in 2008. Ongoing company investment in Avenger continues to yield results, as the aircraft routinely serves as a CCA surrogate for advanced autonomy development and testing in both government programs and company-funded research and development. The company's XQ-67A Off-Board Sensing Station jet, developed in collaboration with the U.S. Air Force Research Laboratory, offers a cutting-edge model for autonomous collaborative platforms with advanced airborne sensing and served as a flying prototype for YFQ-42A Dark Merlin.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Triple Explosion: Spring Festival Gala, Livestreaming, and Offline Presence Trigger Value Realization for Shoucheng Holdings

HONG KONG, Feb 23, 2026 - (ACN Newswire via SeaPRwire.com) – During the Year of the Horse Spring Festival, momentum in the "Hard Tech" sector continued to surge, with the humanoid robotics industry becoming a market focal point following its stellar performance on the Spring Festival Gala stage. Shoucheng Holdings (0697.HK) has emerged as a core target for post-holiday capital market positioning due to a series of heavy-hitting moves. These include the operational launch of the Taozhu New Creation Hub - a comprehensive robotics technology experience, sales, maintenance, and service center—followed by the dual boost of Spring Festival Gala exposure and New Year's Eve livestreaming conversions. Coupled with the positive signal of continuous recent share buybacks, the company’s solid industrial layout and clear earnings growth are expected to trigger a formal valuation recovery.By establishing a closed-loop of "Offline Landing + Strategic Investment + Traffic Conversion + Buyback Support," Shoucheng Holdings has not only demonstrated its deep layout in the robotics track but has also provided the capital market with a high-certainty investment logic through concrete industrial actions and capital behavior. The window for valuation recovery has officially opened.I. Grand Opening of the Offline Complex: Solidifying the Foundation for MonetizationAs the traffic dividends from the Spring Festival Gala and livestreaming were released, Shoucheng Holdings officially launched Taozhu New Creation Hub, its flagship robotics technology retail brand. This complex captures the core of the offline smart consumption track and injects deterministic growth into Shoucheng’s performance. It serves as a solid physical carrier to convert gala traffic and livestreaming orders, marking a new stage in Shoucheng’s full-chain service layout for offline robotics commercial scenarios.Integrated Ecosystem: The Hub constructs an "Experience + Sales + After-sales + Investment" full-model ecosystem."Store-Factory" Innovation: Utilizing an innovative "front-store, back-factory" layout, it includes a robotics maintenance and repair workshop created in collaboration with Accelerated Evolution to provide one-stop services.Market Validation: With an exhibition area exceeding 400 square meters, the Hub serves as a core scenario for investee companies to implement technology and validate market demand.Strategic Store Matrix:Wangfujing APM Store: Located in a premier trendy commercial district, focusing on "Trend Tech + First-Store Economy," targeting consumers aged 18–35.Capital Airport T2 Store: Situated in a core transportation hub with 35 million annual passengers, targeting the "40-minute pre-boarding decision" window with portable and practical smart products.This layout is a key execution of Shoucheng’s "Capital + Scenario + Ecosystem" strategy. By capturing consumer demand through digital means, it provides investee companies with valuable data for product iteration, forming a virtuous cycle of "Industry + Consumption + Maintenance".II. Dominance of the Gala Trio: National-Level Endorsement of Ecosystem StrengthThe Year of the Horse Spring Festival Gala featured a humanoid robot cluster performance as its most high-tech highlight. Among the four core robotics companies featured, three - Unitree Robotics, NOETIX Robotics, and Galbot - are Shoucheng Holdings' portfolio companies. This dominant presence provides national-level brand endorsement for the offline scenarios.The three portfolio companies demonstrated world-class capabilities across core tracks:Unitree Robotics: Deployed a 16-robot formation in the program "Wu BOT," performing high-difficulty martial arts. It achieved world-firsts in continuous parkour flips and rapid maneuvers (up to 4m/s) using self-developed dexterous hands.NOETIX Robotics: Earned the title of "Exclusive Bionic Humanoid Robot Partner" for the gala. Its "Xiaowantong N2" and "Xiaobumi" consumer products displayed lifelike facial expressions and synchronized breathing movements, signaling the acceleration of robots entering the home.Galbot: Debuted as the "Designated Embodied AI Model Robot". Its robot, "Xiao Gai," autonomously performed real-time tasks—such as picking up glass shards and folding clothes—driven by its "AstraBrain" Embodied AI model.This collective appearance is a result of Shoucheng's long-term deep layout, building a complete investment matrix across core components, whole units, and "intelligent brains".III. New Year's Eve Live-streaming: Immediate Traffic MonetizationOn the night of the Gala, Shoucheng Holdings launched the "PoBiren (Barrier-Breaker) Initiative" Live-streaming event, becoming the only industrial investor in the sector to achieve immediate traffic conversion. This successfully closed the loop of "Offline Landing - Stage Exposure - Online Traffic - Order Conversion".Solving Pain Points: The livestream addressed the "unreachable" nature of online consumption through product demonstrations and professional technical interpretations.Seamless Integration: It linked online orders to the Taozhu New Creation Hub for offline delivery and maintenance.Professional Branding: By sharing industry trends from an investor's perspective, Shoucheng deepened consumer trust and solidified its leadership in hard tech investment.ConclusionShoucheng Holdings has achieved a triple breakthrough in national exposure, immediate traffic conversion, and offline operations. Under the resonance of these multiple benefits and continued buybacks, the logic for both valuation and performance enhancement is further strengthened, allowing Shoucheng to lead the hard tech investment track and provide long-term stable returns to investors. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Galaxy Payroll Group Renews Five-Year Strategic Cooperation Agreement with NIKE China Holding HK Limited (Macau Branch)

HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – February 22, Galaxy Payroll Group Limited (NASDAQ: GLXG) (“Galaxy” or the “Company”), a Nasdaq-listed human resources solutions provider, today announced that it has formally renewed a five-year strategic cooperation agreement with NIKE China Holding HK Limited (Macau Branch) (“Nike Macau Branch”).Five-Year Renewal with Comprehensive HR Service CoveragePursuant to the agreement, the renewed cooperation term will commence on December 1, 2025 and continue through November 30, 2030. During this period, Galaxy will continue to provide Nike Macau Branch with a comprehensive suite of human resources outsourcing services, including local payroll processing, attendance and leave management, social security and tax compliance filings, as well as advisory services relating to labor regulations and employment policies.This integrated service model is designed to enable Nike Macau Branch to focus on its core retail and brand operations while enhancing overall organizational efficiency and compliance management.Strategic Renewal Reflects Client Confidence and Enhances Revenue VisibilityThe renewal marks an important milestone in the long-standing relationship between the parties and reflects the continued trust placed in Galaxy’s professional capabilities, compliance standards, and service delivery quality by a leading international brand.The execution of a multi-year agreement is expected to enhance the Company’s revenue visibility and cash flow stability over the next five years, further aligning with its capital markets strategy of building a high-quality, resilient, and sustainable business model. While the agreement provides for long-term cooperation, actual results may vary and remain subject to market and operational conditions.Local Expertise and Scalable Service Infrastructure as Core Competitive AdvantagesSince its establishment in 2013, Galaxy has focused on the Hong Kong and Macau markets while progressively expanding its cross-regional service capabilities. The Company has developed deep expertise in Hong Kong and Macau labor laws, taxation, and social security regulations, forming a strong local compliance foundation.Through a service framework that combines standardized operational processes with customized solutions, Galaxy delivers consistency and scalability across its client base. Its proprietary payroll and attendance management platform enhances operational efficiency while supporting data security and business continuity, serving as a key differentiator in attracting and retaining multinational enterprise clients.Throughout prior phases of cooperation, Galaxy has supported Nike Macau Branch in navigating complex employment and compliance environments. The Company’s solutions have demonstrated reliability in accuracy, responsiveness, and risk control, providing a solid foundation for this long-term renewal.Looking Ahead: From Service Delivery to Value Co-CreationEntering the new cooperation cycle, Galaxy intends to further optimize payroll workflows and intelligent attendance systems within the existing service framework. Through enhanced data integration and periodic management reporting, the Company aims to support the client’s ongoing efforts toward standardized and digitalized human resource management.The parties have also agreed to retain flexibility to expand the scope of services through supplemental agreements, enabling the partnership to evolve in alignment with the client’s business development.The renewal of this five-year strategic agreement not only represents long-term recognition of Galaxy’s professional value, but also underscores the sustainability of its business model. It is expected to further strengthen the Company’s brand presence in the Hong Kong, Macau, and broader Asia-Pacific human resources outsourcing markets, while serving as a replicable benchmark case for multinational retail, sports, and consumer brands.As global enterprises increasingly prioritize compliance efficiency, cost optimization, and organizational resilience, Galaxy continues to leverage its localized expertise, robust service infrastructure, and high-quality client base to build sustainable long-term growth momentum.The Company’s management commented: “We will continue to place service capability at the core of our growth strategy, deepen strategic cooperation with existing high-quality clients, and proactively expand relationships with multinational and regional enterprises that offer long-term value, with the goal of delivering steady and sustainable returns to our shareholders.”Contact informationJune TuoTel: (852) 5983-9260Phone: (86)1392-3804-279Intelligent Joy Limited Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Graphene Manufacturing Group Ltd. Engages AJO Capital Inc. for Marketing and Investor Awareness Services

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - February 23, 2026) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to announce that the Company has entered into an advertising services agreement (the "Agreement") dated February 19, 2026 with AJO Capital Inc. ("AJO"), whereby AJO will provide marketing and investor awareness services to raise public awareness of GMG, including without limitation, original news articles, podcast and interview content creation, newspaper, television, radio and industry network distribution, as well as social media support (the "Services"). GMG has agreed to a monthly payment of US$26,500 for the provision by AJO of the Services. The Agreement commenced on February 19, 2026 and has an initial term of four (4) months unless earlier terminated. The Agreement may be renewed upon mutual written agreement at least thirty (30) days prior to the expiration of the initial term, subject to any modifications to compensation and payment terms as the parties may agree.AJO is a private company based in New York, United States dedicated to providing financial information and media and communication services. The Company will not issue any securities of the Company to AJO as compensation. To the Company's knowledge, AJO and its directors and officers are arm's length from the Company and do not have any interest, direct or indirect, in the Company or its securities nor do they have any right to acquire such an interest.About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information, please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward-looking statements", are not historical facts, are made as of the date of this news release and include without limitation, services to be provided by AJO, term and termination of the Agreement and compensation payable to AJO pursuant to the Agreement.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions regarding the services to be provided by AJO, covenants by AJO under the Agreement, length of the term of the Agreement, termination of the Agreement and compensation payable to AJO pursuant to the Agreement, that the Company will not issue any future securities to AJO as compensation under the Agreement, that AJO acts at arm's length to the Company and none of AJO, its directors nor officers have any direct or indirect interest in the Company and its securities nor do they have any right to acquire such interests. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation, failure by AJO to render services in accordance with the Agreement, breach of the Agreement by either parties, early termination of the Agreement and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285033 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com